NOCIONS all publications
NOCIONS all publications
Roberta Gualdani - Principal Investigator
My research project involves looking for recurrent TRP ion channel mutations in patients suffering from severe chronic pain, in order to understand whether there is a genetic predisposition to the development of the pain conditions, and to develop personalized therapies to normalize the activity of the mutant channels. To this end, I combine the most advanced state-of-the-art techniques for the biophysical and pharmacological study of ion channels, including electrophysiology, fluorescence spectroscopy, biochemistry, structural modelling. I have also a wide experience in ion channel drug discovery and in the development of genetically modified mouse models for in vivo experiments.
Group members
Publications
2025
Conditional deletion of TRPC1 channel modulates synaptic plasticity, long term depression, and memory extinction in Fragile X syndrome mice
iScience
Issa F, Yerna X, Parpaite T, Jabbour C, Schakman O, Tajeddine N, Gualdani R, Gailly P
28(8):113085.
2024
Editorial: Chronic pain: what is the mechanism?
Front Pharmacol
Adams JD, Hsieh CL, Gualdani R
15:1496510.
2023
hERG stereoselective modulation by mexiletine-derived ureas: Molecular docking study, synthesis, and biological evaluation.
Arch Pharm (Weinheim)
Milani G, Budriesi R, Tavazzani E, Cavalluzzi MM, Mattioli LB, Miniero DV, Delre P, Belviso BD, Denegri M, Cuocci C, Rotondo NP, De Palma A, Gualdani R, Caliandro R, Mangiatordi GF, Kumawat A, Camilloni C, Priori S, Lentini G
356(10):e2300116.
2022
Lipoyl-Based Antagonists of Transient Receptor Potential Cation A (TRPA1) Downregulate Osteosarcoma Cell Migration and Expression of Pro-Inflammatory Cytokines
ACS Pharmacol Transl Sci
Francesconi O, Corzana F, Kontogianni GI, Pesciullesi G, Gualdani R, Supuran CT, Angeli A, Kavasi RM, Chatzinikolaidou M, Nativi C
5(11):1119-1127.
2022
Prdm12 modulates pain-related behavior by remodeling gene expression in mature nociceptors.
Pain
Latragna A, Sabaté San José A, Tsimpos P, Vermeiren S, Gualdani R, Chakrabarti S, Callejo G, Desiderio S, Shomroni O, Sitte M, Kricha S, Luypaert M, Vanhollebeke B, Laumet G, Salinas G, Smith ESJ, Ris L, Bellefroid EJ.
163(8):e927-e941.
2021
Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission
Sci Rep
Kreis A, Desloovere J, Suelves N, Pierrot N, Yerna X, Issa F, Schakman O, Gualdani R, de Clippele M, Tajeddine N, Kienlen-Campard P, Raedt R, Octave JN, Gailly P.
11(1):17600.
2021
Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies
Pharmacol Rep
Cavalluzzi MM, Budriesi R, De Salvia MA, Quintieri L, Piarulli M, Milani G, Gualdani R, Micucci M, Corazza I, Rosato A, Viale M, Caputo L, Franchini C, Lentini G.
73(1):172-184.
2020
Human ether-à-go-go-related potassium channel: exploring SAR to improve drug design
Drug Discov Today
Cavalluzzi MM, Imbrici P, Gualdani R, Stefanachi A, Mangiatordi GF, Lentini G, Nicolotti O.
25(2):344-366.
2020
Amyloid Precursor Protein (APP) Controls the Expression of the Transcriptional Activator Neuronal PAS Domain Protein 4 (NPAS4) and Synaptic GABA Release
eNeuro
Opsomer R, Contino S, Perrin F, Gualdani R, Tasiaux B, Doyen P, Vergouts M, Vrancx C, Doshina A, Pierrot N, Octave JN, Gailly P, Stanga S, Kienlen-Campard P.
7(3):ENEURO.0322-19.2020.